patient

Presenter: Mikkael Sekeres Professor of Medicine, Chief, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine Miami, FL, USA Release Date: December 20, 2024 Congress: ASH 2024 Area: Hematology Description: Mikkael A. Sekeres…

Several years ago, I wrote an emotionally difficult article titled "Will I Reach My Goal?" It was about a book I was writing. The book describes my life and what it was like being hard of hearing in the 60s and 70s without any support in the schools. It covers my experiences…

Key Points VEN plus HMA induces superior response rates in patients with R/R AML than conventional salvage therapy. The VEN plus HMA combination allows for a safe and effective bridging to allo-HCT. Abstract The B-cell lymphoma 2 inhibitor venetoclax (VEN) in combination with…

Recent advances in acute myeloid leukemia (AML) come from studies investigating younger (age<60 years) adults or older (age≥75 years) or less fit adults. Uncertainty exists for the management of otherwise healthy adults with AML in their 60s and 70s, which also represents a…

Ziftomenib plus standard cytarabine and daunorubicin chemotherapy was well tolerated with consistent safety and continued to show “robust clinical activity” in patients newly diagnosed with NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML)…

Two new studies led by researchers at Washington University School of Medicine in St. Louis have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer. The studies — both conducted in…